Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, SERB has acquired exclusive US rights to the ticagrelor reversal agent PB2452 (bentracimab), a novel, monoclonal antibody fragment, from SFJ. SFJ will remain responsible for the ongoing trials of bentracimab and will work with SERB to submit the BLA.
Lead Product(s): Bentracimab
Therapeutic Area: Hematology Product Name: PB2452
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: SFJ Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 11, 2023
Details:
Company recieved positive opinion of CHMP of Voraxaze® (glucarpidase) based on clinical data and real world experience. Voraxaze reduces toxic plasma methotrexate concentration in adults and children may quickly lower MTX levels and avoid further systemic damage.
Lead Product(s): Glucarpidase
Therapeutic Area: Pharmacology/Toxicology Product Name: Voraxaze
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: BTG Specialty Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 25, 2021
Details:
BTG Specialty Pharmaceuticals has a portfolio of market-leading emergency care products, including CroFab®, Voraxaze®, and DigiFab®.
Lead Product(s): Glucarpidase
Therapeutic Area: Pharmacology/Toxicology Product Name: Voraxaze
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: BTG Specialty Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 02, 2021